Commonwealth Equity Services, LLC Outlook Therapeutics, Inc. Transaction History

Commonwealth Equity Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$0.22 - $0.66 $8,140 - $24,420	37,000 Added 58.73%	100,000 $39,000
Q3 2023 Oct 23, 2023	BUY	$0.2 - $1.78 $7,600 - $67,640	38,000 Added 152.0%	63,000 $14,000
Q2 2023 Aug 10, 2023	SELL	$1.02 - $1.89 $1,552 - $2,876	-1,522 Reduced 5.74%	25,000 $44,000
Q1 2023 May 11, 2023	BUY	$1.0 - $1.35 $10,000 - $13,500	10,000 Added 60.53%	26,522 $28,000
Q2 2022 Jul 19, 2022	BUY	$0.91 - $2.01 $15,035 - $33,209	16,522 New	16,522 $16,000
Q4 2021 Jan 31, 2022	SELL	$1.27 - $2.23 $27,332 - $47,994	-21,522 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$2.12 - $2.76 $45,626 - $59,400	21,522 New	21,522 $46,000
Q3 2020 Nov 05, 2020	SELL	$0.61 - $1.6 $12,200 - $32,000	-20,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$0.56 - $1.41 $5,600 - $14,100	10,000 Added 100.0%	20,000 $25,000
Q1 2020 May 11, 2020	BUY	$0.51 - $1.08 $5,100 - $10,800	10,000 New	10,000 $6,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.